Sphingolipids are comprised of a backbone sphingoid base that may be phosphorylated, acylated, glycosylated, bridged to various headgroups through phosphodiester linkages, or otherwise modified. Organisms usually contain large numbers of sphingolipid subspecies and knowledge about the types and amounts is imperative because they influence membrane structure, interactions with the extracellular matrix and neighboring cells, vesicular traffic and the formation of specialized structures such as phagosomes and autophagosomes, as well as participate in intracellular and extracellular signaling. Fortunately, "sphingolipidomic" analysis is becoming feasible (at least for important subsets such as all of the backbone "signaling" subspecies: ceramides, ceramide 1-phosphates, sphingoid bases, sphingoid base 1-phosphates, inter alia) using mass spectrometry, and these profiles are revealing many surprises, such as that under certain conditions cells contain significant amounts of "unusual" species: N-mono-, di-, and tri-methyl-sphingoid bases (including N,N-dimethylsphingosine); 3-ketodihydroceramides; N-acetyl-sphingoid bases (C2-ceramides); and dihydroceramides, in the latter case, in very high proportions when cells are treated with the anticancer drug fenretinide (4-hydroxyphenylretinamide). The elevation of DHceramides by fenretinide is befuddling because the 4,5-trans-double bond of ceramide has been thought to be required for biological activity; however, DHceramides induce autophagy and may be important in the regulation of this important cellular process. The complexity of the sphingolipidome is hard to imagine, but one hopes that, when partnered with other systems biology approaches, the causes and consequences of the complexity will explain how these intriguing compounds are involved in almost every aspect of cell behavior and the malfunctions of many diseases.
a, ⁎ J. L. W. Thudichum wrote in 1876 that through chemistry one could understand "…the nature of evils in the shape of disease, and the means of curing or mitigating them" [1] and soon thereafter, in his classic treatise The Chemistry of the Brain [2] , described an enigmatic compound he named "sphingosin." Within a century, the chemical structures of thousands of individual sphingolipids (as the category was later named by Herb Carter) [3] had been elucidated [4] , 1 and a substantial fraction of these compounds were known to be involved in diseases due to defective sphingolipid turnover (Niemann-Pick disease, Gaucher, etc.) [4] [5] [6] (for discussion of the diseases involving acid ceramidase, see the review by Schuchman and coworkers in this monograph) [7] . Soon thereafter, the first successes in treatment were underway [8] . By the end of the twentieth century, sphingolipids were known to be involved in essentially all aspects of cell regulation as well as almost every type of disease. For examples, phospho-and glyco-sphingolipids are the binding targets for a large number of bacteria, bacterial toxins, and viruses [9] (see also the review by Gulbins and coworkers in this monograph) [10] ; disruption of de novo sphingolipid biosynthesis accounts for the toxicity, teratogenicity and carcinogenicity of fumonisins, which are common food contaminants in many parts of the world (in addition, the finding that fumonisins inhibit ceramide synthase was the first discovery of diseases caused by disruption of sphingolipid biosynthesis) [11, 12] ; abnormalities in one subunit of serine palmitoyltransferase (SPTLC1) cause hereditary sensory neuropathy type 1 (HSN1) (which represents the first human genetic disease to be attributed to mutation in a gene for sphingolipid biosynthesis) [13, 14] ; many categories of sphingolipids have long been known to be abnormal in cancer [15] and are now known to participate in many of the mechanisms used by cells to coordinate signals from the external environment with cell division and survival [16, 17] furthermore, they have been shown in vivo to be orally chemopreventive in experimental animals [18] [19] [20] , appear to have chemotherapeutic potential in human clinical trials [21] , and may even provide new strategies for immunotherapy [22] [23] [24] (for more information on sphingolipids and cancer, also see the reviews in this monograph by Levade and co-workers and Ghidoni et al.) [25, 26] ; many categories of sphingolipids are also being implicated in cardiovascular disease [27] , diabetes and the so-called lipotoxicity [28] , Alzheimer's disease [29] [30] [31] [32] and many others too numerous to list here (for recent reviews, see [33] and other chapters in this recent book on Sphingolipid Biology as well as in this monograph). There is, indeed, an evolving field of sphingolipid-based therapeutics [34] . A challenge for this field is to find clear paths through the complex mechanisms and sometime contradictory findings due at least in part to the large number of structurally and metabolically interrelated bioactive species.
To complicate matters further, sphingolipids are engaged in biological functions at multiple levels, and it is not implausible for the following sequelae of events to occur: (i) in the basal state (which may be defined as the state immediately before addition of an agonist or toxic challenge, or as a selected starting point for a progressive biological event, such as the cell cycle), an ensemble of membrane sphingolipids will be present in a particular region of, say, the plasma membrane where they help define the physical properties of the membrane and possibly interact with proteins in that membrane, the extracellular matrix or neighboring cells; (ii) in response to receptor activation or other stimulus, the sphingolipid composition may change due to addition, removal or metabolism, altering (iii) the membrane architecture with respect to the mobility, conformation and/or composition of the other proteins and lipids, and (iv) producing sphingolipid metabolites that may serve as second messengers to activate or inhibit specific downstream targets. In the course of these changes, some of the metabolites may promote major changes in membrane morphology such as the formation of phagosomes, autophagosomes and other specialized structures, which can also have both structural and signaling components. Thus, if asked whether changes in sphingolipids reflect signaling or membrane reorganization, the answer would be "both." It would be useful to have a single term, perhaps "sphingaling," for the entire spectrum of mechanisms whereby sphingolipids influence cell behavior.
While there are many views about where one might begin to study such a complex subject, an approach favored by Thudichum was to "…proceed by a severe process, that of analysis, for nothing less than the results of analysis of work done can establish as proved what many feel as a sentiment…." [1] . And he also considered this to be the approach that would ultimately result in a better understanding of disease: "The reader will thus be better able to appreciate the reasons which have caused me to give so much attention to the chemolysis of the principles extracted from the brain, and to surmise the grounds which influence me not to coincide with those who propose to avoid this laborious effort, and to carry on research by a kind of fishing for supposed disease-poisons, of which, according to my view of the subject, the attempt of the boy to catch a whale in his mother's washing-tub is an appropriate parabole." [2] .
In this millennium, Thudichum's approach would be called "systems biology" with investigators approaching biology using the tools of genomics, proteomics, metabolomics, lipidomics and all of the other "omics" at their disposal. Therefore, this review is written from the perspective of emerging "sphingolipidomic" technologies, and attempts to overlay what these methods can conveniently measure thus far (mostly the lipid backbones and a few of the complex species) within a framework of knowledge about the metabolism and function of these molecules. It will also highlight what are likely to be the first deliverables of sphingolipidomic approaches, which are the surprises that fall outside of the scope of the original hypothesis-which in some cases may even cause a change of paradigm.
Structures and properties of the lipid backbone(s) of sphingolipids
Although the names and structures of the lipid backbones of sphingolipids are now generally known, as more investigators have entered this field and expanded the types of organisms that are studied, the likelihood of encountering the same term for different molecular species has also increased (for example, "sphingosine" from most mammalian sphingolipids will be comprised mainly of an 18-carbon alkyl chain whereas that from fruit flies has primarily 14 carbons) [35] . Thus, there is a growing need for greater clarity in defining the specific compounds that have been analyzed and a more standardized nomenclature [36] .
Sphingoid bases
Sphingolipids are defined by the presence of a backbone sphingoid base (i.e., a 2-aminoalk[ane or ene]1,3-diol with 2S,3R stereochemistry), which can be distinguished by chain length, number of double bonds, and whether or not there are additional hydroxyls by the nomenclature described in the legend to Fig. 1 . Although different organisms can display considerable variation in the sphingoid base backbone [37] , there are usually only a few structural variants in any one species; for example, humans have primarily sphingosine (d18:1) (often abbreviated "So"), sphinganine (d18:0) (often abbreviated "Sa" or "DHSo" for dihydrosphingosine) and 4-hydroxysphinganine (t18:0) (often abbreviated "Phyto" for phytosphingosine, an old name for this compound) (Fig. 1 ) plus small amounts of the longer chain length homologs d20:1 and d20:0 and in skin, 6-hydroxy-sphingosine (6-t18:1). In contrast, insects often contain sphingoid bases with a shorter alkyl-chain length (14 and 16 carbons) [35] and plants have sphingoid bases with the double bonds in additional positions along the alkyl chain [38] (Fig. 1) .
One of the distinctive features of sphingoid bases is that they bear a net positive charge at neutral pH, which is rare among naturally occurring lipids [39] , and with aqueous solubilities >1 μM, they can relatively easily move among different membranes [40] . However, it should also be borne in mind that the pKa of the amino group (7 and 8) is lower than usually found in simple amines [41] (due in part to intramolecular hydrogen bonding), therefore, a substantial fraction is uncharged and able to move across membrane bilayers, as schematically depicted in Fig. 2 . Likewise, they can become trapped in vesicles that have an acidic pH [42] , and under some conditions So can act as a lysosomotrophic agent [43] .
Sphingoid bases are also bound by albumin, and are usually administered to cells as a 1:1 (mol:mol) complex to solubilize the sphingoid base as well as serve as "buffer" the detergent effects [44] . For more information about biophysical considerations for sphingoid bases and ceramides, the reader is referred to Fig. 2 . Schematic representation of some aspects of sphingolipid dynamics in cells. The diagram shows the fate of sphingolipids made de novo in the endoplasmic reticulum (ER) from serine and palmitoyl-CoA by serine palmitoyltransferase (SPT) to sphinganine (Sa), and formation of dihydroceramide (DHCer) by ceramide synthases (CS) and desaturation of DHCer to Cer by DHCer desaturase (DES). This is followed by trafficking to and through the Golgi, where sphingomyelin (SM) and most glycosphingolipids (GSL) are made and delivered to the plasma membrane (PM); alternatively, the (DH)Cer (and possibly other sphingolipids) may be incorporated into other intracellular compartments such as mitochondria or autophagosomes. Also shown is synthesis of galactosylceramide (GalCer) in the lumen of the ER and synthesis of sphingomyelin (SM) in the PM by SM synthase (SMS), as well as SM turnover via sphingomyelinases (SMase) to Cer as well as the downstream metabolites sphingosine (So) and sphingosine 1-phosphate (SoP). The turnover of sphingolipids (including both long-chain and short-chain Cer) occurs in several intracellular locations, but for simplicity, the production in the PM and vesicles such as lysosomes are shown to illustrate how the products can be recycled, degraded, or in the case of SoP, secreted from the cell. the review by F.M. Goñi and A. Alonso in this monograph [45] , and for more complex sphingolipids, the review by B. Maggio [46] .
Phosphorylation of So increases the polarity considerably although it is nonetheless difficult to prepare solutions of S1P because the charge is internally neutralized as the zwitterion; therefore, it is helpful to consult the technical literature when using this compound (http://www.avantilipids.com/SyntheticSphingosine-1-phosphate.asp). N-methyl-derivatives have also been reported but rarely [47] , however, in this report, we will describe a situation where they have been found in cells using mass spectrometry.
Ceramides
The term ceramide (Cer) is often used specifically for Nacylsphingosines, which is the preferred practice, however, when investigators use a method that does not distinguish among backbone species (such as analysis by thin-layer chromatography under most conditions, or the diglyceride kinase assay), the term will likely include all N-acyl-sphingoid bases, regardless of the backbone. The terms "dihydroceramide" (DHCer) and "phytoceramide" (PhytoCer) are often used to designate "ceramides" with these other backbones (i.e., Nacyl-sphinganines and N-acyl-4-hydroxysphinganine, respectively), and when the fatty acyl chain length is specified, this is often shown by the carbon number before the name, such as C16-Cer for N-palmitoyl-sphingosine. Here, too, it is helpful to use the shorthand nomenclature suggested by the Lipid MAPS Consortium [36] where ceramides would have a d18:1 backbone, dihydroceramides would have d18:0, etc. and the amide linked fatty acids can also be designated by this nomenclature (e.g., N-palmitoylsphingosine would be d18:0/16:0).
The fatty acids are typically 16 to 26 carbon atoms in length (with shorter and longer species being found under special conditions, for example, the water barrier of skin has a 30-carbon, ω-hydroxyl fatty acid) and mostly saturated, with the most common unsaturated species in mammals being nervonic acid (Fig. 1) . The ceramides of skin, epithelial cells, and other sources (such as plants) often have α-hydroxy-fatty acids (Fig. 1) .
Since both alkyl chains of most ceramides are saturated, the phase transition temperatures of sphingolipids are usually quite high, typically > 37°. Naturally occurring ceramides are highly hydrophobic and essentially insoluble in aqueous medium (cmc < 10 − 10 M). When studies require the delivery of ceramides to enzyme assays or cells, this water-insolubility is often circumvented using detergents or liposomes, organic solvents (e.g., ethanol and dodecane, 98:2), or short-chain analogs (such as N-acetylsphingosine, C2-Cer, through Noctanoylsphingosine, C8-Cer) [44] . Use of these analogs is informative, but the short-chain Cer have very different biophysical properties than the natural species [48] ; furthermore, when added to cells, the short-chain fatty acid may be removed and replaced with a long-chain fatty acid [49] as depicted schematically in Fig. 2 (although this changes the molecular species, the products are ceramides with a more physiological composition). Also useful are fluorescent analogs, such as N-[6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]hexanoylceramide (NBD-Cer) that are readily taken up by cells and have proven very useful in studies of sphingolipid transport and metabolism because the NBD-fatty acid is not recycled into other lipid classes [50] . NBD-DHCer is also desaturated and can serve as an in situ substrate for DHCer desaturase [51] .
Although the aqueous solubility of long-chain Cer is low, they can nonetheless be considered as amphiphiles because the hydroxyl group at the first carbon and the amide bond are hydrophilic moieties [48, 52] . Some of the biological responses to Cer generation are probably due to their influence on the structure of membrane rafts and caveolae, promotion of the membrane curvature, and induction of membrane "leakiness" to aqueous solutes (which has been proposed to play a role in release of pro-apoptotic mediators from mitochondria) [53, 54] . One would additionally predict that production of Cer could be used to promote membrane curvature by trapping of the Cer on one leaflet by phosphorylation, which may be how this metabolite participates in phagocytosis [55] . Ceramide 1-phosphate also plays a major role in cell signaling [56] . Addition of headgroups to produce sphingomyelins (SM), glycosphingolipids, and 1-O-acylceramides also changes the properties; however, a discussion of more complex sphingolipids falls outside the scope of this review.
Lipidomic analysis of sphingolipids
A lipidomic analysis would be defined as "sphingolipidomic" analysis if it determines all of the molecular species of sphingolipids, which for mammals probably numbers in the tens of thousands considering that there are over 400 headgroup variants, at least a half dozen sphingoid bases (if one includes minor species) and in most sphingolipids, about a dozen major and minor fatty acid variants. Hence, currently available methods are able to analyze only subsets of the full sphingolipidome [57] [58] [59] . Fortunately, this includes at least one approach (liquid chromatography, electrospray tandem mass spectrometry, LC ESI MS/MS) that is capable of providing structure specific and quantitative analysis of all of the "signaling" backbone species (Cer and Cer 1-phosphates, sphingoid base and sphingoid base 1-phosphates and others) [57, 58] ).
Mass spectrometry has been applied to sphingolipids for at least four decades using many ionization methods, including MALDI and electrospray (ESI), and mass analyzers, such as sectors, quadrupoles (Q), time-of flight (TOF), ion traps and Fourier-transform ion cyclotron resonance (FT-ICR) (for primary references to these methods see the reviews cited above). Some of the advantages of mass spectrometry are that it provides: (a) a high level of specificity with regard to identification of complex compounds via molecular mass, especially when analyzed by tandem mass spectrometry (MS/ MS and MS n modes); (b) levels of sensitivity that are orders of magnitude lower than classical techniques, so compounds can be detected even if they are present in attamol to fmol amounts (usually analyzed with ∼10 6 cells or even fewer); (c) a signal response can be correlated to analyte concentration provided there are appropriately matched internal standards to normalize for differences in ionization and fragmentation of individual molecular species; and (d) a dynamic range of several orders of magnitude for some forms of MS/MS, which allows analysis of compounds that vary in abundance over this same range in biological samples (for example, typically high abundance sphingolipids such as sphingomyelins versus signaling metabolites). To achieve these goals, a number of decisions regarding the handling of the samples (both extraction methods and separation of isomeric and isobaric species prior to mass spectrometry), internal standards, ionization technique, instrument, and mass spectrometry scanning method must be made judiciously.
The success of mass spectrometric analyses fundamentally depends on the gas phase chemistry of the compounds of interest and whether or not they produce ions that are useful as unique and sensitive identifiers for the individual species. In this regard, sphingolipids have proven to be particularly amenable to mass spectrometric analyses because they are relatively easily ionized, and many fragment to products that are characteristic for the headgroup and backbone subclasses [58] (Fig. 3) . For examples, both long-chain bases and complex sphingolipids readily ionize via positive ion ESI to form primarily (M + H) + ions, and sphingoid base-1-phosphates, SM, sulfatides, and gangliosides may also form (M-H) − ions via negative ion ESI. Furthermore, the fragmentation profiles for both sphingoid bases and many complex sphingolipids (Figs. 1 and 3) provide information about the headgroups and types of sphingoid bases and fatty acids in the backbones. However, when fragmentation leaves the ion on the headgroup rather than the ceramide backbone (as occurs with SM, for example), only the overall composition of the backbone is determined, not the nature of the individual components, unless newer techniques are used (M. Cameron Sullards, personal communication). To deal with the complexity of the compounds that are being analyzed (especially for the higher order glycosphingolipids) and, hence, the potential number of fragments, a systematic nomenclature has been developed which describes these fingerprint fragmentations [60] [61] [62] [63] .
As part of its goal of developing mass spectrometric methods that will eventually allow analysis of the entire lipidome, the LIPID MAPS Consortium (www.lipidmaps.org) has developed extraction protocols, mass spectrometric methods using ESI and both triple quadrupole and hybrid quadrupole-ion trap instruments, and internal standards (which have recently been made available for purchase by Avanti Polar Lipids, Alabaster, AL) for analysis of mammalian sphingolipids up to mono-and usually di-hexosylceramides (for sphingolipids, these have been published [58] , but will continue to undergo refinement). At present, the published methods are able to analyze all of the species shown in Fig. 4 as well as compounds such as lysosphingomyelin, psychosine and N-methylsphingoid bases. 
Formation of the lipid backbones of sphingolipids
Biosynthesis of the lipid backbone of sphingolipids is not only important to form the lipid "anchor" for the more complex downstream products [64] [65] [66] [67] , but also because many of the biosynthetic intermediates are highly bioactive and can affect cell behavior (and when disrupted, result in disease) [64] [65] [66] [67] . De novo begins with the condensation of serine and a fatty acyl-CoA (e.g., palmitoyl-CoA for ceramides with an 18-carbon sphingoid base backbone) by serine palmitoyltransferase (SPT) [68] to form 3-ketosphinganine (3KSa), followed by reduction of 3KSa to sphinganine (Sa), which is then N-acylated to DHCer and (in most cases) desaturated to Cer in the endoplasmic reticulum [69, 70] as shown in Figs. 2 and 4 (Cer can also be made by recycling of So, as also shown).
Serine palmitoyltransferase (SPT) belongs to a family of pyridoxal 5′-phosphate (PLP)-dependent α-oxoamine synthases [71] that are, in most cases, soluble homodimers, whereas SPT is (in most species) a membrane-bound heterodimer (with the known exception being the SPT from Sphingomonas paucimobilis) [72] . In mammals, two gene products (SPTLC1 and SPTLC2) are necessary for SPT activity, whereas in yeast a third subunit has been found [73] . Human SPTLC1 and SPTLC2 have ∼ 20% identity, and the SPTLC2 subunit has a conserved lysine residue in a consensus pyridoxal phosphate-binding motif [71] that is lacking in SPTLC1 [74] which implies that SPT has only one catalytic active site. Missense mutations of SPTLC1 that are at the interface of the SPTLC1/SPTLC2 and close to the presumed active site lysine of SPTLC2 [75] have been linked to the most common hereditary sensory neuropathy type I (HSN1) [13, 14] . Both components of the SPT heterodimer are required for activity, and expression of each subunit has been found to affect the amounts of the other, even in mice with reduced expression of one of the subunits [76] .
SPT activity can be regulated transcriptionally and posttranscriptionally. Both positive and negative regulation at a transcriptional level has been seen with a number of agents, including endotoxin and cytokines [77] , UVB irradiation [78] , and other agents [79] . Certain types of synthetic and naturally occurring agents change SPT activity with no effect on SPT mRNA amount, such as retinoic acid [80] , resveratrol [81] , etoposide [82] , and N-(4-hydroxyphenyl) retinamide (4-HPR) [83] . A major regulator of activity is the supply of the substrates, serine and palmitate [84] . SPT appears also to be regulated by S1P, although the mechanism is not known [85] .
3-Ketosphinganine reductase (3KSR) is located in the ER with the active site facing the cytosolic side [86] . The gene Fig. 4 . De novo sphingolipid biosynthesis highlighting the branching of the pathway at acylation of sphinganine by the lass (CerS) family ceramide synthases. Starting at the top is the biosynthesis of sphinganine, which can be acylated by the lass gene products shown with their fatty acyl-CoA preference. The abbreviation shows the sphingoid base backbone using the abbreviated nomenclature of Fig. 1 followed by the alkyl-chain length and number of double bonds of the fatty acid. Each dihydroceramide (DHCer) can be desaturated to the comparable ceramide (Cer) and both have several possible fates, as illustrated by the overlay within the dashed box on the left: conversion to (DH)Cer phosphate, (DH)CerP; (DH)sphingomyelin, (DH)SM; glucosyl(DH)Cer, Glc(DH)Cer; galactosyl(DH)Cer, Gal(DH)Cer; or hydrolysis to the free sphingoid base, that can be phosphorylated (SaP and SoP). Not shown are the equivalent conversions that could be effected for backbone 4-hydroxydihydroceramides (phytoceramide). One additional pathway shown at the left is the synthesis of N-acetyl-sphinganine and -sphingosine (C2Cer) by transacetylation (TA) from platelet activating factor (PAF).
(TSC10) was first identified in yeast [87] , followed by the discovery that the 3KSR of mammals is encoded by a gene previously described as the follicular lymphoma variant translocation-1 (FVT-1) gene. The mRNA of FVT-1 is transcribed ubiquitously in different tissues of humans and mice, with greater abundance of steady state mRNA observed in placenta, lung, kidney, stomach, and small intestine [86] . The FVT-1 protein is predicted to have three transmembrane domains; the N-terminus is in the lumen of the ER, whereas the active site residues and the C-terminus are in the cytosol [86] .
Reduction of 3KSa is not thought to be rate limiting because KSR activity in vitro is higher than for SPT [88] ; however, 3KSa based sphingolipids have been reported in mitochondria [89] (although the structural assignment is somewhat inconclusive because these authors also reported the presence of an implausible t21:1 phytosphingosine in mitochondria). We have not seen 3KSa in cells by ESI MS/MS, however, one can envision that one might be able to overload the reduction step by producing 3KSa at an elevated rate. To test this hypothesis, we examined Hek cells that were stably transfected with both SPTLC1 and SPTLC2 (obtained from David Uhlinger and David Perry), which have a 4-8 fold increase in de novo sphingolipid biosynthesis. Even in these cells, there were no detectable 3-keto-sphingolipids when analyzed by mass spectrometry; however, when the cells were incubated with supplemental serine and palmitate, 3-ketodihydroceramides were readily detected [58] (Fig. 5) . Therefore, it appears that when there is "overflow" of 3KSa, it is more likely to be acylated than accumulate as the sphingoid base.
(Dihydro)ceramide synthase(s)
At one time, it was thought that cells may contain one or two (dihydro)ceramide synthase(s) that would utilize a wide spectrum of sphingoid bases and fatty acyl-CoA's [90] . The first genes coding for Cer synthase(s) were identified in Saccharomyces cerevisiae, where two genes (Lag1p and Lac1p) were found to account for synthesis of yeast Cer (which contain C26-fatty acids) [91, 92] , and a lower molecular weight protein was later found to be required for activity [93] . Mammalian homologs of Lag1p were then identified and the first (lass1) was shown to be highly selective for stearoyl-CoA and to make C18-(DH)Cer [94] , which was followed by characterization of additional substrate selective (DH)Cer synthases [94, 95] . It is now known that there are at least six genes for (DH)Cer synthase(s) family (LASS1-LASS6) in mammalian cells [96] and, which appear to optimally utilize the fatty acyl-CoA's shown in Fig. 4 , although some of these assignments should be regarded as tentative until the enzymes are purified and the activities can be examined more rigorously (the most definitive proof has been for lass5 because it has been purified and the reconstituted activity still selects C16:0 fatty acyl-CoA) [97] . It has also been suggested by Futerman and colleagues that these genes should be renamed CerS as a more logical name for Cer synthases than LASS) [98] . All but LASS1 contain a HOX domain, a transcription factor involved in developmental regulation [95] [96] [97] [98] [99] , but it would seem to be necessary for the LASS proteins to be post-translationally modified (i.e., proteolytically cleaved) for these motifs to function as transcription factors (which would be interesting, indeed).
As the LASS genes for individual subspecies of Cer have been identified, links between specific Cer's and cell regulation/ disease have become easier to discern. For example, Ogretmen and co-workers [100] have discovered that head and neck tumors have lower proportions of C18-Cer than neighboring normal tissue and that transfection of the LASS1 gene into head and neck tumor cells in culture suppressed cell growth. Relatively little is known about this subclass of ceramides. However, in a "sphingolipidomic" analysis of cells for Sarah Spiegel's lab [101] , we have observed that administration of exogenous So causes significant enrichment of C18-Cer. A similar finding has been made using cells overexpressing SPT (Ying Liu and A.H. Merrill, Jr., unpublished data), therefore, it appears that LASS1 is subject to regulation by the availability of its sphingoid base substrate.
Cer synthase activity is inhibited by fumonisins, a family of mycotoxins produced by Fusarium verticillioides [102] that cause a wide range of diseases of agriculture animals (equine leukoencephalomalacia and porcine pulmonary edema) and humans (cancer and birth defects) [12] . The structure of fumonisin B1 and the characteristics of the inhibition suggest that the aminopentol backbone competes for binding of the sphingoid base substrate, whereas the anionic tricarballylic acids may interfere with binding of the fatty acyl-CoA [103] . The inhibition of Cer synthase(s) causes the accumulation of Sa and Sa-1-phosphate as well as depletion of complex sphingolipids-all of which are likely to contribute to the toxicity/ carcinogenicity [103, 104] and teratogenicity [12, 105] of the fumonisins. There is also an intriguing interplay between sphingolipids and TNFα in modulating fumonisin-induced hepatotoxicity [106] [107] [108] which might be related to the known ability of cytokines to induce serine palmitoyltransferase [77] and other suggested links between de novo sphingolipid biosynthesis and turnover in TNFα signaling and toxicity [109, 110] .
Dihydroceramide desaturase(s)
After the initial suggestion that incorporation of the 4,5-trans-double bond of So occurred at the DHCer level [111] , this was established conclusively by a combination of in vivo labeling studies [112] and development of an assay for this highly labile enzyme [113] . DHCer desaturases were then cloned from plants [114, 115] , leading to the subsequent identification of the desaturase genes from many organisms: Δ 4 -desaturase (DES1) genes of Homo sapiens, Mus musculus, Drosophila melanogaster, and Candida albicans and a bifunctional Δ 4 -desaturase/C4-hydroxylase (DES2) from Homo sapiens and Mus musculus [116] [117] [118] [119] . Although both DES1 and DES2 genes exist in yeast, Saccharomyces cerevisiae sphingolipids contain mainly phytoSo as a sphingoid base [120] , which is a so fairly prevalent in skin, intestine, and kidney cells [121] . DES activity is influenced by the alkyl chain length of the sphingoid base and fatty acid, the stereochemistry of the sphingoid base (D-erythro versus L-threo-dihydroceramides), the nature of headgroup, and the ability to utilize alternative reductants [113] . Introduction of the 4,5-double bond can be analyzed using NBD-DHCer, which reveals interesting features about the stereoselectivity of the reaction and subsequent metabolism [51] .
Relatively little is known about DES1 and DES2, but the desaturation reaction can be reproduced in vitro using either DHCer or dihydrosphingomyelin [113] with NADH or NADPH and molecular oxygen as co-substrates, and appears to be part of the cytochrome b5 electron transport system of the ER. DHCer desaturase(s) are inhibited by dithiothreitol (DTT) and Nacetylcysteine, hence, one can envision that elevation of cellular thiols could suppress formation of ceramides [113] . The characteristics of this enzyme are similar to other desaturases, and inhibitors and redox effectors known to affect Δ 9 -stearoylCoA desaturase and Δ 1 -plasmanyl-ethanolamine desaturase severely inhibited dihydroceramide desaturation [113, 122] .
Generation of ceramide by the reverse reaction of ceramidase
Ceramidase catalyzes the hydrolysis of Cer, but the reverse reaction (Cer synthesis from free fatty acid and So) is not only possible due to microscopic reversibility, but has been found to be relatively rapid under certain conditions [123, 124] . The reverse reaction has strict stereochemical requirements for D-erythro-sphingosine [123, 124] , D-erythrosphinganine, and D-erythro-phytosphingosine but can accommodate a wide spectrum of a fatty acids, including both saturated and unsaturated fatty acids [123] and chain lengths varying from C8 to C22 [124] . Detergents, pH, and various lipids such as cardiolipin, phosphatidylcholine, and lysophosphatidylcholine can affect the hydrolysis reverse activity of ceramidase(s) [124] .
Generation of C2-ceramide by platelet-activating factor (PAF)-dependent transacetylase
Sphingoid bases can be acetylated by a platelet-activating factor (PAF)-dependent transacetylase that transfers the acetyl group from PAF in a CoA-independent manner [125] . The PAFdependent transacetylase is widely distributed among the tissues and appears to be less active with Sa than So [126] . Nonetheless, C2-DHCer has been found in cells and animals treated with fumonisin B1 (as well as the untreated controls) [103] , and it is not clear if this is produced by the PAF transacylase or a more generic acetyltransferase used in detoxification of xenobiotics.
Generation of ceramide by turnover of complex sphingolipids
In contemplating the sources of the lipid backbones in cells, one must take into account not only the compounds that are derived from de novo sphingolipid synthesis, but also that Cer are also produced by turnover of complex sphingolipids that are in the cell or taken up from culture medium. The major sources for the ceramide backbone are the hydrolysis sphingomyelin (SM) by sphingomyelinase(s) (SMase) [90, [127] [128] [129] [130] , the hydrolysis of GlcCer and GalCer by glycohydrolases [131] , and dephosphorylation of Cer1P by lipid phosphatase(s) [132] .
Sphingomyelinase(s) are distinguished according to their pH optima and subcellular localization, and to date several have been characterized: lysosomal acid sphingomyelinase (aSMase), zinc ion-dependent secretory sphingomyelinase (sSMase), neutral magnesium ion-dependent SMase (nSMase), and alkaline SMase (bSMase) [133] . Inducers of SM turnover are diverse and include the tumor necrosis factor (TNF) receptor family ligands, anticancer drugs, oxidants, and conditions known to induce cellular stress [133] . These are all categorized as phospholipase C's, i.e., cleave the phosphodiester bond on the side of the linkage to Cer, so the products are Cer and choline phosphate. The venom of the brown recluse spider and some other organisms contain SMase D's that produce Cer 1-phosphate and choline, and a similar activity has been found in some bacteria, which has been suggested to reflect lateral gene transfer [134] . Recent studies (K. Uyesugi et al., manuscript in preparation) have found that the venom also hydrolyzes ceramide phosphoethanolamine, which is the major phosphosphingolipids in flies and many other insects.
Reversal of synthesis is another potential source of Cer because SM synthases convert diacylglycerol (DAG) plus SM to Cer and phosphatidylcholine (PC). This activity is found mostly localized in the Golgi and, to some extent, the plasma membrane [135] . It has been suggested that the ratios of PC/SM and DAG/Cer are intrinsically related, with possible implications for cross-talk between glycerolipid and sphingolipid signaling [130] .
Turnover of glycosphingolipids is also an important source of Cer and the degree to which the backbone is salvaged versus degraded varies considerably depending on the cell type and conditions [136] . One of the first reports suggesting that glycosphingolipids may contribute to Cer signaling has recently been published [137] .
Formation of long-chain ceramide from exogenous short-chain ceramide
In studies of the effects of short-chain Cer, investigators at the Medical University of South Carolina found that exogenously added short-chain Cer undergoes deacylation followed by recycling of the So backbone by reacylation with a long-chain fatty acid [49] , and because the reacylation was inhibited by FB 1 [49] , they suggest that Cer synthase may be responsible.
Removal of ceramide by hydrolysis or incorporation into other sphingolipids
The partner to formation of the lipid backbones is their removal, and this occurs both by turnover and utilization to biosynthesize more complex sphingolipids.
Ceramide turnover to sphingosine
Ceramidases catalyze the hydrolysis of Cer to free fatty acid and sphingoid base. There are three types of mammalian ceramidases classified by the pH optimum of the activity and subcellular localization: acid ceramidase [138] , neutral/alkaline ceramidase [123, 139] , and alkaline ceramidase [140] . Ceramidase controls cellular Cer amount by responding to extracellular stimuli, such as interleukin-1β [141] , nitric oxide [142] , oxidized low density lipoprotein [143] , and platelet-derived growth factor [144] .
Sphingosine metabolism
Cer degradation is the only known source of intracellular So [145] (i.e., there is no known reaction that adds the 4,5-double bond to Sa directly), therefore, free So is either derived from sphingolipid turnover or taken up from an exogenous source (which could be a substantial route since blood is thought to contain ca 0.1 to 1 μM So and S1P) [146, 147] . In addition, Sa shares many of the biochemical properties of So [41] , and Sa (as well as Sa1P) amounts can be very high, as exemplified by the levels that are achieved when cells are treated with fumonisin B1 to inhibit Cer synthase [103, 148] .
Cellular amounts of So are controlled (c.f., Fig. 2 ) by: (a) removal by reacylation, as mentioned above for the recycling of the So from short-chain Cer, and as part of recycling of other categories of sphingolipids [131] ; (b) removal by phosphorylation by So kinases (SphK1 and SphK2) [149] , which are well established to be important mediators of cell migration, survival, differentiation, angiogenesis, and development [150] , (c) production from S1P by the hydrolysis by S1P phosphatase (S1PP) [151] , and possibly other lipid phosphatases, and (d) irreversible degradation by S1P lyase (SPL), a PLP-dependent enzyme that catalyzes the cleavage of S1P to ethanolamine phosphate and a long-chain aldehyde [152] . The turnover of sphingoid bases does not only remove potential signaling molecules but also provides precursors for other lipids, and in at least one system, the turnover of sphingoid bases has been estimated to account for as much as one third of the ethanolamine phosphate in phosphatidylethanolamine [153, 154] .
Studies of S1P lyase using mass spectrometry to characterize the consequences of overexpressing lyase activity illustrate the types of surprises that use of sphingolipidomics can produce [152] . One might predict from the scheme shown in Fig. 2 that overexpression of the lyase would not only deplete cells of S1P (as well as Sa1P), but also reduce Cer and other complex sphingolipids because sphingoid bases in general would be diverted to degradation. As predicted, the cells had reduced baseline So and S1P but had elevated stress-induced Cer generation that correlated with increased cell death due to apoptosis. The most likely explanation for this seeming paradox is that de novo sphingolipid biosynthesis was elevated in S1P lyase overexpressing cells because S1P appears to function as a feedback regulator of the pathway [85] .
Removal of ceramide by metabolism to more complex sphingolipids
Cer is at the branchpoint for biosynthesis hundreds of complex sphingolipids as summarized in [155] and can be seen in www.sphingomap.com. The initial metabolites that are formed directly from Cer (as well as from DHCer) in mammalian cells are shown in the left overlay of Fig. 4 (SM, GlcCer, GalCer and Cer1P, etc.) and each (as well as a less prevalent pathway, 1-acylation) are discussed briefly below:
Sphingomyelins
Cer is metabolized to SM at the cis and medial Golgi [156, 157] and plasma membrane [158, 159] by SM synthases that catalyze the transfer of phosphorylcholine from phosphatidylcholine to the 1-hydroxyl of Cer [160, 161] . A family of integral membrane proteins have been identified as responsible for SM synthesis; SMS1 localized to the Golgi, and SMS2 localized to the plasma membrane [162] .
Ceramide-1-phosphates
Cer is phosphorylated by Cer kinase (CERK) , a cytosolic enzyme that has some similarity with So kinases, but additional conserved regions that are unique to CERK [163] , CERK is active with a variety of Cer with fatty acyl chain lengths > 4 carbons, and displays higher activity when the sphingoid base has a 4,5-trans double bond [164] . Cer1P synthesis has been reported to be inhibited by a novel F-12509A oletin isomer, K1, which has been reported to inhibit CERK without effecting other So kinases [165] .
Glucosylceramides and galactosylceramides
GlcCer is synthesized by UDP-glucose:Cer glucosyltransferase (CGlcT, or sometimes abbreviated GCS) on the cytosolic side of the Golgi apparatus, and possibly the smooth ER, which utilizes Cer and UDP-glucose. [166] [167] [168] A number of inhibitors of CGlcT have been developed [169] , such as D,Lthreo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) [170] , PPMP [171] , N-butyldeoxygalactonojirimycin (NB-DNJ), [172] N-alkyl-deoxygalactonojirimycin (N-alkyl-DGJ) [173] and in blocking GlcCer synthesis, these compounds can increase Cer [174] . Some of the P-glycoprotein antagonists also limit GlcCer synthesis [175] , however it is not known whether this is by interference with lipid flippase(s) [176] or through CGlcT interaction. Once Cer reaches the Golgi, it (as well as GlcCer) also must traverse the membrane for synthesis of SM and the higher order glycosphingolipids.
Galactosylceramide (GalCer) is synthesized in the lumen of the ER by UDP-galactose:Cer galactosyltransferase (CGalT, or sometimes abbreviated CGT) [177, 178] . Because GalCer is synthesized in the lumen of the ER, the substrates must traverse the membrane. Little is known about the ability of Cer to flip across the ER membrane, however, UDP-galactose transport is thought to involve the UDP-galactose transporter 2 (UGT2), a splice variant of UGT1 that contains an ER locating di-lysine motif (KVKAS) [179] and in some cases, UGT1 [177] .
Although this review is focused on the lipid backbones of sphingolipids, it warrants mention that GlcCer [180] [181] [182] [183] [184] [185] [186] [187] [188] , GalCer [189] , and downstream metabolites are also modulators of cell behavior, hence, if interference with backbone metabolism also affects these compounds, they may contribute to changes in cell phenotype. In addition, glycosphingolipid turnover is clearly important as exemplified by the nature of the pathologies associated with glycosphingolipid storage diseases [190] [191] [192] [193] [194] [195] [196] [197] [198] . Although accumulation of the substrate of the defective hydrolase plays a role in these diseases (e.g., GlcCer in Gaucher's disease [199] [200] [201] and GalCer in Krabbe's disease [202] ), accumulation of other highly bioactive compounds, such as psychosine (a lysoglycosphingolipid that lacks the fatty acyl sidechain but retains the carbohydrate headgroup) also appears to play a role in pathogenesis [203, 204] .
Other ceramide metabolites
In addition to these major products, 1-O-acylceramide is synthesized by 1-O-acylceramide synthase which transfers the sn-2-acyl group of phosphatidylethanolamine or phosphatidylcholine to Cer [205] . 1-O-acylceramide synthase is encoded for by the lecithin:cholesterol acyltransferase-like lysophospholipase gene (LLPL) [206] , and is inhibited by PDMP [207] .
Some sphingolipids are covalently attached to protein, for examples: ω-hydroxy-Cer and -GlcCer are attached to surface proteins of skin [208, 209] and inositol-phosphoCer are used as membrane anchors for some fungal proteins [210, 211] .
Subcellular localization of sphingolipid biosynthesis and turnover
The scheme in Fig. 2 for the localization of sphingolipid biosynthesis and turnover depicts only a small fraction of the intracellular compartments -and within a compartment, the presence of different microdomains -that can determine whether a sphingolipid of interest has access to the pertinent enzyme or target, which is clearly required for a complete picture of sphingolipid metabolism and function. Unfortunately, the analysis of cellular metabolites by mass spectrometry is only beginning to be able to discern the subcellular localization of the compounds [212] but this is undoubtedly the next step in the evolution of this technology. The trafficking of sphingolipids has been part of many elegant studies [213] [214] [215] and is discussed by Futerman and co-workers in another review in this monograph [216] . The relatively recent finding [217, 218] of a critical Cer trafficking protein, CERT, illustrates how there are undoubtedly participants in these processes that yet await discovery.
Biological activities of the lipid backbones of sphingolipids
Mindful that the lipid backbones of sphingolipids are involved not just in "signaling" but also "sphingaling," the following section provides a brief overview of the molecular targets of the bioactive sphingolipid backbones (So and Cer and the 1-phosphates) (Fig. 6 ) as a context for understanding the need for lipidomic analysis, and some surprises that have surfaced in these analyses.
Sphingosine, other sphingoid bases and sphingoid base 1-phosphates as bioactive species
The first sphingolipids that were shown to affect an identifiable cell signaling target in vitro and with intact cells was the inhibition of protein kinase C by So [219] [220] [221] . Followup structure-function studies discovered that essentially all stereoisomers as well as N-methyl-derivatives (mono-, di-and tri-methyl-), chain length homologs, etc. are inhibitory [41, 222] . The inhibition by the N-methyl-derivatives was presumed to be of marginal physiologic interest because these Fig. 6 . Summary of some of the key signaling targets that are affected by the lipid backbones of sphingolipids and their metabolic interrelationships (protein kinase A, PKA; 3-phosphoinositide-dependent kinase 1, PDK1; sphingosine dependent kinase 1, SDK1; protein kinase C, PKC; protein phosphatase 1, PP1; protein phosphatase 2A, PP2A; acid sphingomyelinase, aSMase; phospholipase A 2 , PLA 2 ; sphingosine-1-phosphase, S1P). Also noted is that the biophysical properties of ceramides and ceramide 1-phosphates may play important roles in cell signaling by changing raft properties, making membranes leaky, etc. compounds had only been noted indirectly [47] ; therefore, it was much to our surprise when we have recently found substantial amounts of N-methyl-and N,N,N-trimethyl-sphingoid bases (as well as the N,N-dimethyl-derivative, but in barely detectable amounts) by mass spectrometry in Hek 293 cells treated with exogenous So (Fig. 7) . This figure also illustrates another change that is often seen upon addition of exogenous So, a marked elevation in Sa1P (and depending on the time point and concentration, we often also see elevations in Sa and S1P, not shown). The elevation in Sa (1-phosphate) is likely due to the competition of exogenously added So for Cer synthase, diverting a portion of the newly made Sa to Sa1P (c.f., Fig. 2) . Therefore, when investigators add exogenous sphingoid bases to cells (including as short-chain Cer), there are changes in a large number of endogenous metabolites as well as the induction of new species, such as the N-methyl-derivatives, that may be contributing to the cell behavior(s) under study.
Other targets that have been identified for sphingoid bases (Fig. 6 ) are a So dependent protein kinase (which has been identified as a proteolytic fragment of protein kinase Cδ, also termed the protein kinase Cδ kinase domain, PKCδKD) that phosphorylates 14-3-3 protein [223] ; PDK1 [224] ; protein kinase A type II, which is activated by So independent of cAMP [225] ; casein kinase [226] ; and a number of ion channels [103, [227] [228] [229] [230] . In addition, So has recently been suggested to be an endogenous agonist for the CB1 cannabanoid receptor (and for this receptor also to bind the So analog FTY720) [231] . In addition, in yeast, Sa and 4-hydroxySa (phytosphingosine) affect several protein kinase pathways and appear to play key roles in signaling, for example, for heat shock [232] . Less has been done in mammalian systems to link changes in free sphingoid bases with downstream responses, with the exception of pathological conditions where sphingoid bases are elevated several orders of magnitude in animals that consume toxic amounts of fumonisins [233] .
Sphingoid base 1-phosphates are, arguably, fast becoming the most extensively studied sphingolipid mediators, and rather than discuss them here, the reader is referred to the review in this series by Spiegel and co-workers [233] or others from this lab on targeting S1P in cancer [234] , neural and vascular development [235] , and asthma [236] , for just a few of the important links between S1P and disease. It is also worth noting in Fig. 6 , that en route to formation of sphingoid base 1-phosphates (and after their dephosphorylation, in the reverse direction), one removes or produces another highly bioactive compound (So) -indeed, it is often overlooked that free sphingoid bases are often as, or more, cytotoxic than ceramides [237] (hence, in some cases where S1P is protective against cell death, might this be due to protection of the cells against accumulation of So or another sphingolipid that might otherwise cause cytotoxicity?). Continuing this train of thought, So is also produced from/or can lead to Cer, or which can be produced from/lead to Cer1P or more complex sphingolipids. These interrelationships underscore the difficulty of knowing which bioactive compounds are important in a given biological process; however, this opportunity for coordinate regulation of many signaling pathways may be the biological rationale for this pathway.
Other "lyso"-type sphingolipids (i.e., ones with a free amino group) include sphingosylphosphocholine (lysoSM) [238] [239] [240] and psychosine (e.g., galactosylsphingosine) [203, 204] . Both are highly bioactive and, especially for the former, emerging as likely new categories of backbone lipid signals.
Ceramides and Cer1P as bioactive species
Soon after sphingosine was suggested to be a sphingolipid second messenger, Cer also became a candidate [241] and proved to be the first backbone sphingolipid metabolite that fulfilled the traditional requirement of a second messenger signaling system, namely that it was produced in response to cell stimulation, Cer (or at least shorter chain analogs) were able to induce comparable cell responses, and at least one protein was identified as a direct target for Cer in studies with intact cells and in vitro [242, 243] . Of tremendous value to these studies was the finding that the target (protein phosphatase PP2A, and later, other Cer targets) [243, 244] was not activated -or at least only weekly activated -by dihydroCer (e.g., C2-DHCer vs. C2-Cer) [245] , which ruled out non-specific, membrane disruption as the mechanism of action of the exogenously added Cer. This selectivity has been seen for all of the other Cer targets shown in Fig. 6 (except for the biophysical effects of Cer), which has resulted in the impression that DHCer are not involved in cell regulation. This may, indeed, not be correct as will be discussed later in this review.
Although there are many signaling pathways that are affected by Cer, at present, the following appear to be direct targets of Cer:
Phosphoprotein Phosphatases 1 and 2A
These multimeric proteins are activated by Cer [244, 246] and perform critical functions for cell growth, survival and apoptosis [247] . Activation of PP2A can induce apoptosis by inactivating the anti-apoptotic target Akt [248] and Bcl2 [249] , and activating the pro-apoptotic proteins Bad [250] and Bax [251] . Activated PP1 appears to induce apoptosis through alternative splicing Bcl-x and Caspase-9 [252] . Another target of Cer, KSR (kinase suppressor of ras), may be downstream of PP2A activation [253, 254] . KSR is an essential upstream regulator of TNFα-stimulated ERK1/ERK2 activation, most likely mediated via direct phosphorylation of Raf-1 [255] , and can protect intestinal epithelial cells from under going apoptosis during TNFα [256] . Recent structural elucidation of the KSR C1 domain by NMR has revealed the presence of a cysteine rich region which are normally associated with lipid and protein; hence, Cer may also interact with KSR directly [257] .
Protein kinase C (PKC)
Many members of the PKC family are affected by Cer. Cer promotes phosphorylation and translocation of PKCα, PKCδ and PKCε [258] [259] [260] to the Golgi but inhibits the juxtanuclear translocation of PKCβ 2 [261, 262] . PKCξ is activated by the direct binding of Cer, which leads to the formation of a proapoptotic complex with prostate apoptosis response-4 (PAR4) [263] . Activated PKCξ also regulates gene expression through the nuclear factor-kappa B (NF-κB) [264] activity, while it modulates alternative splicing of mRNA by phosphorylating hnRNPA1 to causes it to translocate to the nucleus [265] .
Cathepsin D
Cer was first found to bind to cathepsin D when this protease was isolated by Cer affinity chromatography [266] . Production of Cer by acid sphingomyelinase (a-SMase) in response to TNFα, CD95, and chemotherapeutic agents [267] activates cathepsin D to induce caspase-independent apoptosis. The endosomal protease activity of cathepsin D is responsible for cleaving and activating Bid [268] , a pro-apoptotic protein that affects the release of cytochrome c and activation of caspase 3 and 9.
Other possible targets of Cer
It has been reported that Cer directly binds to activate stressactivated protein kinase (SAPK/JNK) and induces glomerular epithelial cells to undergo apoptosis [269] . One can also envision that any Cer binding protein, such as CERT and enzymes that utilize Cer as an enzymatic substrate (or product), may function as Cer sensors if they either serve as a depot (buffer) or possibly transduce information to other regulatory pathways via protein-protein interactions. More information about Cer binding proteins has been provided in the review by Hannun and colleagues in this monograph [270] .
As noted earlier, the biophysical properties of Cer allow membranes to undergo structural changes that can be viewed as analogous to the activation or inactivation of a signaling target [271] . Lipid microdomains (rafts) that are enriched in sphingolipids promote assembly of receptors and proteins that favor signaling activation, and this has been suggested to contribute to signaling via CD95 [272] , FasL [273] , FcγRII [274] , UV-induced caspase activation [275] , and the clustering of the P2X 7 receptor responsible for PLA 2 activation [276, 277] . Induction of membrane "leakiness" [52] [53] [54] might be regarded as analogous to opening of an ion channel, and if the channel is large enough, perhaps sufficient to allow efflux of pro-apoptotic mediators.
Phosphorylation of Cer to produce Cer 1-phosphate is multifunctional, with the consequences being (not necessarily in this temporal order nor ranking of importance): (a) consumption of Cer, therefore, termination of structural and signaling (i.e., "sphingaling") processes that depend on Cer per se; (b) appearance of a negatively charged phospholipid that, presumably, will be located on only one side of the bilayer, hence, could promote membrane curvature; (c) alteration of the surface charge of the membrane and its capacity to bind ions, proteins, etc.; (d) selective interactions with other membrane components (within the membrane or bound to the surface) to induce conformation changes that activate or inhibit the biochemical function(s) of the cellular components (such as to activate a protein kinase); and, (e) creation of a new species that can be acted upon by enzymes, binding proteins, etc. to terminate these changes and progress to the next step in the chain of events linked to these molecules (which may be another step in a signaling cascade or reestablishment of the initial "basal" state).
As discussed in the review in this monograph by A. Gómez-Muñoz and coworkers [278] , production of Cer 1-phosphate has been associated with key regulatory processes such as stimulation of DNA synthesis and induction of proliferatingcell nuclear antigen [279] as well as inhibition of apoptosis (through suppression of acid sphingomyelinase activity to prevent accumulation of Cer) [280] , stimulation of PI3-kinase leading to activation of the transcription factor NF-κB and upregulation of anti-apoptotic Bcl XL [281] , and activation of phospholipase A2 and eicosanoid production [282] [283] [284] . Cer1P also plays an important role in phagocytosis [55] .
DHCer as bioactive species?
DHCer are generally regarded to be innocuous because they have generally not been found to mimic Cer in studies of Cer targets in vitro nor when short-chain (DH)Cer have been added to intact cells [245] . Therefore, we were quite surprised when mass spectrometric analysis of cells treated with 4-hydroxyphenylretinamide (4HPR, also called fenretinide) -an agent that has heretofore been thought to cause large increases in Cer to induce growth arrest and apoptosis as at least part of the mechanism of action of this cancer chemotherapeutic agent [83, 285, 286] -did not display increases in Cer (Fig. 8, gray bars) (indeed, in some cases, Cer mass decreased), but rather large increases in DHCer (Fig. 8, black bars) . This distinction was overlooked before because the previous studies analyzed Cer by techniques such as thin-layer chromatography or quantitation with diglyceride kinase where the DHCer are not readily distinguishable from Cer. The possibility that agents thought to elevate Cer might instead cause increases in DHCer has only rarely been considered before (an exception being a recent study of the effects of γ-tocopherol on LnCaP cells which also noted an elevation in DHCer) [287] , 2 and raises the question: can DHCer also serve as bioactive species, and if so, how?
From a biophysical perspective, it is relatively easy to envision how DHCer might perform different cell functions than Cer because they have a higher dipole potential compared to Cer, which could decrease the packing density [289] ; they have a lesser tendency than Cer to promote flip-flop [290] ; and are less prone to form membrane channels [291] . In addition to these biophysical properties (or perhaps because of them), we have found a cellular process that can be induced by DHCerthe formation of autophagosomes -and this may be one of the cell regulatory functions of these sphingolipid backbones.
Sphingolipids and autophagy
Autophagy ("self-eating") is a normal physiologic mechanism for the turnover of cellular proteins, excess and damaged organelles [292, 293] , and is sometimes subdivided into three types [294] : microautophagy, where cytosolic components are directly engulfed by lysosomes; chaperone-mediated autophagy, which uses transport proteins to move components into the lysosome; and macroautophagy (which is often referred to as "autophagy," including in this review), where proteins and organelles are sequestered into double membrane vesicles known as autophagosomes that fuse with lysosomes to form autophagolysosomes, where the degradation is completed.
While autophagy is most often thought of as a mechanism to supply essential nutrients during starvation, it is now also considered to be part of ongoing cell maintenance as well as to play important roles in digestion of foreign organisms (xenophagy) and antigen presentation [295] . Autophagy has been described as a "double-edged sword" [296] because it can both contribute to, and protect from, disease [297] . For example, in cancer autophagy can be utilized by tumors as a means to avoid apoptosis in a nutrient and growth-factor limited environment but can also be a chemotherapeutic target by suppression of autophagy or conversion of safe to lethal autophagy (by destabilization of the autophagolysosome and leakage of proteases into the cytoplasm) [298, 299] .
Recent studies have elegantly established that addition of exogenous Cer can induce autophagy, and the autophagy induced by agents such as tamoxifen involves endogenous sphingolipids [300, 301] . To establish that autophagosomes are being formed, these investigations have used: (a) microscopy to establish that structures resembling macroautophagosomes are induced in malignant glioma cells (U373-MG and T98G) and colon cancer (HT29) cells after treatment with C2-Cer; (b) measurement of the rate of protein degradation, one of the functions of formation of autophagosomes, which is increased in HT-29 cells after treatment with C2-Cer (and to show that the effect was attenuated by the autophagy inhibitor 3-methyladenine, 3MA) [302] ; and (c) examination of the appearance of large, acidic vesicular organelles that can be visualized by acridine orange staining (and more specifically, monodansylcadaverine, MDC) and are considered characteristic of autophagic vacuoles, in cells treated with C2-Cer. In a more recent approach that has become feasible due to advances in the understanding of the early molecular events of autophagy, cells have been transfected with a genetic construct for green fluorescent protein (GFP)-tagged LC3 protein (microtubuleassociated protein light chain 3), which is normally distributed throughout the cytoplasm but is recruited to the ER membrane and appears in a punctate pattern early in the formation of autophagosomes [303] . This punctate pattern was observed after the cells were treated with C2-Cer [300] and by other perturbations of sphingolipid metabolism [304] . Therefore, these investigations have shown that Cer induces autophagy by all of the accepted criteria for establishment of this phenomenon.
In addition to the induction of autophagy by exogenous short-chain Cer, Codogno and co-workers [301] have shown that tamoxifen (which elevates endogenous Cer by inhibition of GlcCer synthase [285] ) induces autophagy. This study not only found that changes in endogenous Cer were correlated with autophagy, but also, showed that tamoxifen-induced autophagy was suppressed when Cer synthesis was blocked by the SPT inhibitor myriocin (ISP1) [301] . Therefore, endogenous Cer can serve as a mediator in the induction of autophagy by other agents.
In agreement with these investigations, we have found that transfection of DU145 cells with GFP-tagged LC3 protein results in clustering of GFP-LC3 into punctate structures after addition of C2-Cer (Fig. 9, upper right panel) versus the control cells with vehicle only (Fig. 9, top left panel) . In addition, cells treated with 4HPR (Fig. 9 , lower right panel) also displayed more punctate fluorescence than the control. Because we have found that 4HPR elevates DHCer, not Cer, in these cells (Fig.  8) , DU145 cells were treated with C2-DHCer under the same conditions, which clearly caused GFP-LC3 fluorescence to appear in punctate (autophagosomal) vesicles (Fig. 9, lower  left) . Therefore, exogenous DHCer is able to induce autophagy in DU145 cells, and it is likely that the induction of autophagy by 4HPR is due to the large increase in endogenous DHCer (Fig. 8) . It would be interesting to know if some of the recently developed chemical inhibitors of DHCer desaturase have similar effects on cells [305] .
Possible mechanisms for Cer and DHCer induced autophagy
Exogenously added C2-Cer and elevation of endogenous Cer with tamoxifen increase beclin 1 [301] , an upstream regulator of autophagy [306] . Suppression of beclin 1 expression with siRNA blunted the autophagic response of U-251 glioblastoma cells to C2-Cer, and it is possible that it may facilitate the interaction of PI3K with upstream regulators of autophagy [307] . Class I PI3K and AKT are suppressors of autophagy, and Cer is a well-known activator of PP2A, which inhibits AKT activation [301, 308, 309] . C2-Cer has also been shown to relieve IL-13-mediated inhibition of autophagy [310] , which is thought to involve the class I PI3K/AKT pathway [304] . Induction of autophagic cell death might also involve BNIP3, a cell-death inducing mitochondrial protein that was induced by C2-Cer in U373-MG and T98G cells [300] .
Intriguingly, none of these signaling pathways are known to be induced by both Cer and DHCer, therefore, it is possible that there is another role for these compounds that involves other target(s), or a biophysical effect of (DH)Cer such as the induction of membrane curvature since the formation of autophagosomes involves major changes in membrane architecture. It is also possible that a key mediator is another sphingolipid metabolite(s) of Cer and DHCer (such as the 1-phosphate, since Cer1P is known to play a role in phagocytosis) [55] .
Another backbone lipid metabolite has been implicated in autophagy is S1P [304] . Over-expression of SpkK1 promoted autophagy which was not inhibited by FB1, which indicates its mechanism is not dependent on N-acylation of sphingoid bases (i.e., may be separate from Cer). Unlike Cer-mediated autophagy, SphK1-mediated autophagy was not associated with an increase in beclin 1 protein [304] nor an inhibition of Fig. 9 . Induction of autophagy by N-acetyl-sphingosine (C2Cer), -sphinganine (C2DHCer) and fenretinide (4HPR). DU145 cells were transfected with a GFP-tagged LC3 protein (a marker of autophagosomes) then after 24 h, treated with the shown compounds (at 10 μM) and examined by confocal microscopy after an additional 24 h. The arrows highlight regions where LC3-GFP fluorescence is associated with autophagosomes (Auϕ) versus the cytoplasm (C) and, for reference, the darker nuclear region (Nuc).
AKT or the class I PI3K; however, the downstream regulator of the PI3K/AKT pathway and autophagy inhibitor mTOR was inhibited by SphK1 over-expression. A particularly interesting finding of this study was that suppression of SphK1 expression or activity by an inhibitor caused lethal autophagy, whereas, SphK1 protected cells from apoptosis during starvation. Hence, what one envisions could be happening as cells make more autophagosomes, etc. with respect to the possible consequences for cell survival has been summarized in the model shown in Fig. 10 .
This model begins with the presumption that elevation of Cer or DHCer induces the formation of autophagosomes, which may be a more widely occurring phenomenon that is currently appreciated because even a "classic" inducer of autophagy (i.e., serum starvation) has been seen to elevate Cer [311] . After autophagosomes are formed, they acquire lysosomal enzymes such as acid ceramidase, which will hydrolyze at least some of the Cer (or DHCer) to Sa and So, which will, in analogy to lysosomal degradation of sphingolipids (c.g., Fig. 2 ), will efflux from the autophagolysosome to the cytosol and be reacylated or phosphorylated. The finding that So kinase promotes autophagy that does not progress to cell death suggests that the phosphorylation of Sa and So removes these potentially cytotoxic compounds (since free sphingoid bases are well known to be cytotoxic) [41, 43, 237] , in addition to activating anti-apoptotic targets be controlled by sphingoid base 1-phosphates [101, 149, 233] . Therefore, in the absence of sufficient So kinase activity, sphingoid bases could accumulate, destabilize the autophagolysosomes, and cause release of cathepsins and other cytotoxic factors [312, 313] . This is an attractive scenario because Cer are activators of cathepsin D, which in turn are known to be able to activate caspases and induce apoptosis [266] [267] [268] .
Considering that the functions of autophagy include degradation of damaged proteins and organelles and to enable cells to deal with other stressful (e.g., low-nutrient) conditions, it is not surprising that the pathway would have a mechanism to do so safely, but to switch to a lethal mode when the damage/stress is too severe for the cell to maintain other normal characteristics (such as an undamaged genome, etc.). These descriptors parallel the current thinking about the effects of the lipid backbones of sphingolipids on cell survival versus death, with sphingosine-1-phosphate being primarily an inhibitor of apoptosis whereas Cer and So promote apoptosis. Thus, the scheme in Fig. 10 -even if oversimplified -may serve as a useful model for additional studies of the interplay between sphingolipid metabolism and autophagy because a better understanding of these interrelationships could lead to new strategies for controlling autophagy in muscular and neurodegeneration, infection, cancer and other disease.
Summarizing comments
That the lipid backbones of sphingolipids play critical roles in membrane structure and signaling is now beyond doubt, but as has been illustrated for autophagy, it is not necessarily clear for a given biological phenomenon if only one compound and its cellular target(s) are sufficient to regulate that cellular function, or if an ensemble of metabolically interrelated compounds are necessary because their effects are synergistic, with the synergy including temporal and/or spatial coordination. Most complex biological processes require many levels of coordinate regulation, and because sphingolipid metabolites are capable of being lethal, one would assume that the regulation of these compounds would be very sophisticated. Indeed, until we have technologies like "sphingolipidomics" in their future, more comprehensive, forms (that allow not only the molecules to be identified and quantified, but also the subcellular locations to be known), our understanding of how a given biologic process is regulated by sphingolipids will be incomplete. It is encouraging, nonetheless, that even if this is a still somewhat of a fishing expedition, the works of many sphingolipidologists -starting with Thudichum -have enlarged the waters so we now have a reasonable chance of finding a whale. The scheme suggests that elevations in ceramide (Cer) and/or dihydroCer (DHCer) by various means (#1) may promote the formation of autophagosomes (#2) that will be converted to autophagolysosomes by incorporation of lysosomal hydrolases, resulting in cleavage of (DH)Cer to sphinganine and sphingosine, (Sa)So (#3). If (Sa)So exit the autophagolysosome (#4), they can undergo phosphorylation to sphinganine 1-phosphate (SaP) and sphingosine 1-phosphate (SoP) by sphingosine kinase (SphK1) (#5a), which should favor cell survival. If efflux is not facilitated by trapping the sphingoid bases in the cytoplasm by phosphorylation, they may accumulate in the autophagolysosome and -perhaps in combination with (DH)Cer -destabilize the membrane (#5b) resulting in release of cathepsins (including cathepsin D, which might be further activated by Cer) (#6a) to ultimately activate Caspases (#6b) and cell death (R.I.P.). their findings and discussions, and in particular Katie Fluke, Chris Haynes, Carrie Pack and May Wang.
